Teva Pharmaceutical Announces Upcoming Conference Call Details

Author: Kelly Martin Updated: 02-18-2025 04:39 PM

Teva Pharmaceutical Industries to Host Key Conference Call

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced an important conference call and live webcast scheduled for 8 AM E.T. on February 24, 2025. This call aims to present new insights regarding the promising Phase 2b results of duvakitug (anti-TL1A) shared at a significant event in the gastroenterological field.

Details of the Conference Call

During the conference call, insights will be shared by Eric Hughes, MD, PhD, the Executive Vice President of Global R&D and Chief Medical Officer. In addition, notable external IBD key opinion leaders will join the discussion, adding their expertise to the conversation about duvakitug's potential therapeutic benefits.

Participation and Access

For those interested in listening to this conference call, registration is essential in advance. You will need to secure a local or toll-free phone number along with your personal PIN.

Live Webcast Availability

A live webcast of the event will be accessible through Teva’s official website, providing an opportunity for stakeholders to stay updated on the latest developments regarding duvakitug.

Playback Options

Following the live session, it will be possible to listen to a replay of the webcast within a 24-hour timeframe, ensuring that all interested parties can catch up on the discussions.

Teva’s Partnership with Sanofi

Teva is collaborating with Sanofi for the co-development and commercialization of duvakitug, marking a significant step in addressing ulcerative colitis (UC) and Crohn’s disease (CD). This partnership involves an equal sharing of global development costs and profits, with Sanofi leading the Phase 3 program and Teva focusing on the commercial strategy in Europe and other specific regions.

About Teva Pharmaceuticals

For over 120 years, Teva Pharmaceutical Industries Ltd. has stood at the forefront of the global pharmaceutical sector. With a dedicated workforce of approximately 37,000 employees across 57 markets, Teva is committed to driving innovation and delivering high-quality medicines that enhance health outcomes on a global scale.

Commitment to Health

Teva's longstanding dedication to improving health reflects its progression in scientific advancement. The company relentlessly seeks to push the boundaries of modern medicine, ensuring that the needs of patients are met through effective treatment solutions.

Contact Information

For media inquiries or further information, reach out to Teva Communications North America via email.

Frequently Asked Questions

What is the purpose of the conference call?

The call aims to discuss new data regarding the Phase 2b results of duvakitug presented at a recent congress.

Who will be speaking during the call?

Key speakers will include Eric Hughes and various external IBD key opinion leaders.

How can I participate in the conference call?

To participate, you must register in advance to receive a local or toll-free phone number and personal PIN.

Is there a way to access the call later?

Yes, a replay of the call will be available within 24 hours on Teva’s website.

What is the partnership between Teva and Sanofi about?

Teva and Sanofi are collaborating to co-develop and commercialize duvakitug for UC and CD, sharing costs and profits equally.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.